NPHC News Nutra Pharma Adopts Famous 2-Headed Snake of St. Louis' World Aquarium
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp., (OTCBB:NPHC) a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis (MS) has announced today
that it has adopted the 2-headed albino rat snake, named “WE”,
from St. Louis’ World Aquarium. WE became
famous in 2006 for being offered online at auction for $150,000.
“We are honored to help support the World
Aquarium by adopting WE,” commented Rik J.
Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Our
support will help continue to educate the public about the importance of
conservation and researching the natural world,”
he added.
Nutra Pharma is currently developing breakthrough scientific treatments
for MS, HIV/AIDS, and Adrenomyeloneuropathy (AMN) using modified cobra
venom and cobratoxin. The company has recently announced it has received
final approval to begin a Phase IIb human clinical trial for the
treatment of AMN.
“Nutra Pharma is the perfect adopter for WE,”
explained Leonard Sonnenschein, President of the World Aquarium. “The
important research on snake venom being conducted by Nutra Pharma
scientists will ultimately help millions of people around the world.
This is just one of the many reasons why we need to focus on conserving
the environment and educating others about the importance of nature and
the resources it provides,” he concluded.
Although terms of the agreement were not disclosed, the funding provided
by Nutra Pharma will be used to directly support educational and
conservation initiatives provided by the World Aquarium (www.WorldAquarium.net)
and the Concert for the Oceans (www.ConcertfortheOceans.org).
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its
subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company's
holding, ReceptoPharm, Inc, is developing technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are discussed
in the Company's filings with the Securities and Exchange Commission
("SEC").The agreement with the World Aquarium should
not be construed as an indication in any way whatsoever of the value of
the Company or its common stock.The Company's filings may be
accessed at the SEC's Edgar system at www.sec.gov.Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
